Navigation Links
Panmira and FLAP LLCs Spun Out of Amira Pharmaceuticals
Date:9/8/2011

SAN DIEGO, Sept. 8, 2011 /PRNewswire/ -- Panmira Pharmaceuticals, LLC and FLAP, LLC, today announced their formation around certain assets spun out immediately preceding the acquisition of Amira Pharmaceuticals, Inc. (Amira) by Bristol-Myers Squibb Company (NYSE: BMY).  Panmira Pharmaceuticals received a number of assets, including Amira's DP2 antagonists, AM211 and AM461, both of which have successfully completed Phase I clinical studies.  FLAP, LLC is a non-operating company with rights to future milestones and royalties from Amira's 2008 licensing deal with GlaxoSmithKline related to the 5-lipoxygenase-activating protein (FLAP) inhibitor program.

"Now that we have successfully completed the sale of Amira to Bristol-Myers Squibb Company, a subset of the former Amira team will focus on completing our partnership efforts for the DP2 program," said Bob Baltera, Chief Executive Officer of Panmira Pharmaceuticals.  "We believe that spinning out these assets will be the best way to maximize their value for Amira's shareholders, and we look forward to accomplishing this goal."

Hari Kumar, Ph.D., Chief Business Officer, added, "Clinical trial results have demonstrated a dose proportional pharmacodynamic (PD) effect and good safety profiles for both AM211 and AM461.  These compounds are primed and ready for Phase II exploration in a number of clinical settings, including asthma, chronic obstructive pulmonary disease (COPD) and eosinophillic esophagitis.  We look forward to having the right partner to help make these plans come to fruition."

While there are no DP2 selective antagonists approved for therapeutic use, there is a strong scientific rationale for the target to be a novel, potentially disease-modifying treatment of asthma, COPD and allergic rhinitis. DP2, also known as chemoattractant receptor-homologous molecule expressed in Th2 lymphocytes (CRTH2), is a high affinity receptor for the prostaglandin D2 and is impli
'/>"/>

SOURCE Panmira Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals to Present Preclinical Data on AM152 , an LPA1 Receptor Antagonist, at the Annual Meeting of the American Thoracic Society
2. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
3. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
4. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
5. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
6. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
7. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
8. Visage Imaging Releases Amira 5.3
9. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
10. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
11. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015  CryoLife, Inc. (NYSE: ... company focused on cardiac and vascular surgery, announced today ... the position of Vice President, General Counsel and Corporate ... directly to Pat Mackin , President and Chief ... is tremendously talented and has extensive legal experience in ...
(Date:4/1/2015)... YORK , April 1, 2015  New York ... their world class Intellectual Properties portfolio with U.S. Patent ... Properties policy. This patent represents a surgical instrument that ... seeing as if it were in the traditional format ... match it against medical databases during surgery, thus providing ...
(Date:4/1/2015)... Ill. and ASPEN, Colo. ... in partnership with the Chris Klug Foundation (CKF), is pleased ... are now being accepted for the award, which will ... quality of life, whether it is a career accomplishment, ... a fulfilling life with family and loved ones. ...
Breaking Medicine Technology:CryoLife Appoints Jean Holloway as General Counsel 2CryoLife Appoints Jean Holloway as General Counsel 3Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 2Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 3Astellas Teams Up with The Chris Klug Foundation on the Bounce Back Award to Recognize Extraordinary Transplant Recipients 2Astellas Teams Up with The Chris Klug Foundation on the Bounce Back Award to Recognize Extraordinary Transplant Recipients 3
... Reportlinker.com announces that a new market research report ... Dialysis Market -2013 http://www.reportlinker.com/p0289800/Global-Dialysis-Market-2009-2013.html ... Technavio Insights forecasts the Dialysis market to grow at ... America and Latin America) having the largest market share ...
... N.C., Sept. 7 VR Mergers & Acquisitions Charlotte ... of Charlotte, NC,s Amramp franchise, a provider of quality ... Charlotte Amramp serves over 50 counties in North Carolina ... largest franchisee in Amramp,s nationwide system. Rick ...
Cached Medicine Technology:Reportlinker Adds Global Dialysis Market -2013 2Reportlinker Adds Global Dialysis Market -2013 3
(Date:4/1/2015)... Royal River Natural Foods, a locally-owned independent ... that found the amino acid creatine, which athletes typically use ... blood pressure. , The report is part of ... Being® ,” which Royal River Natural Foods publishes each month ... learn the latest in nutrition science. Also in the April ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 The panel ... and telematics service providers to build a program that ... and complicated legal implications further down the line. This ... wake of the news that OBD-II port dongles aren’t ... In January, it was reported that Progressive’s Snapshot ...
(Date:4/1/2015)... 2015 Taking an important step forward ... for Nursing Commission for Nursing Education Accreditation (NLN CNEA) ... first NLN CNEA Board of Commissioners. Working with executive ... 15-member board will provide leadership and direction to accreditation ... decisions for nursing programs that seek accreditation from the ...
(Date:4/1/2015)... EAGAN, Minn. (April 1, 2015) —Blue Cross ... companies (Blue Cross) today announced audited financial results for ... income of $61.5 million, reflecting positive investment portfolio performance ... net operating loss of $8.2 million on full-year revenues ... one-tenth of one percent (0.1%). , Blue Cross ...
(Date:4/1/2015)... Diego, CA (PRWEB) April 01, 2015 ... organization, is announcing two continuing medical education (CME) ... is to help practitioners become more confident in ... prevent disease. After completion of these CME courses, ... , The CME courses available are “Vitamin ...
Breaking Medicine News(10 mins):Health News:New Study Finds Strength-Building Supplement Improves Circulation, Retailer Reports 2Health News:TU-Automotive: Office of The Privacy Commissioner of Canada To Set Out Privacy Considerations Surrounding UBI Products 2Health News:TU-Automotive: Office of The Privacy Commissioner of Canada To Set Out Privacy Considerations Surrounding UBI Products 3Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 2Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 3Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 2Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 3Health News:GrassrootsHealth Launches CME Courses about Vitamin D 2Health News:GrassrootsHealth Launches CME Courses about Vitamin D 3
... Seven QHR hospital clients were recently recognized for their complete and ... performance. , ... Brentwood, Tenn. (PRWEB) October 29, 2008 ... their complete and compliant coding practices in Ingenix,s fifth annual study ...
... Hospital researchers report that findings from a new study of ... no presence of antibiotic-resistant bacteria. The study, prompted by the ... and Asia, is among the first in this country to ... The study was published in the Journal of Food, ...
... 29 A new report released,today by the national ... many of this country,s dangerous government-approved drugs and,devices have ... removed or made safer only after women filed lawsuits., ... -- How Drug Companies,Fail To Protect Women and How ...
... Skin Sparing Approaches Offer Effective Cancer Treatment and Restore the ... ... New surgical techniques have,dramatically improved the aesthetic results of ... conserving, surgical approaches provide women undergoing biopsy and,surgical treatment for ...
... parents, GREENSBORO, N.C., Oct. 29 Is there ... to the sponsorship of Lorillard Tobacco Company.,Families throughout the ... of a,real doctor when it comes to communicating an ... Dr. Michael Popkin, psychologist and,founder of Active Parenting Publishers ...
... vaccines delivered following major funding award. , A vaccine ... a fatal form of brain disease will be delivered ... available thanks to multi-million dollar funding. , The parasite ... and 50,000 deaths from brain disease in the developing ...
Cached Medicine News:Health News:Seven QHR Hospital Clients Ranked Among Best of Best In Coding, According to Ingenix 2Health News:Seven QHR Hospital Clients Ranked Among Best of Best In Coding, According to Ingenix 3Health News:Rhode Island Hospital study finds local retail meat safe from antibiotic-resistant organisms 2Health News:New Report Shows How Drug Industry Immunity Would Endanger Women 2Health News:Many Breast Cancer Patients Are Not Receiving Most Advanced Breast Conserving Surgical Techniques, New Study Finds 2Health News:Many Breast Cancer Patients Are Not Receiving Most Advanced Breast Conserving Surgical Techniques, New Study Finds 3Health News:Anti-Smoking Web Site Helps Parents Plug Into Prevention 2Health News:Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award 2Health News:Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award 3
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
For the quantitative in vitro determination of creatinine in serum, plasma or urine....
For the quantitative in vitro determination of Total Protein in serum and plasma...
Medicine Products: